CPT code 0021U is a Proprietary Laboratory Analyses (PLA) code for Apifiny®, a serum immunoassay combined with flow cytometry that measures eight autoantibodies and applies an algorithm to produce a prostate cancer risk score. As a PLA code, 0021U is specific to a single manufacturer's test and signals an emerging, proprietary diagnostic intended to support clinical decision-making in prostate cancer risk assessment. Nationally, PLA codes like 0021U are important because they capture use of novel, vendor-specific laboratory tests that may influence screening pathways and referral patterns.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for the test, the typical service setting and type, and a summary of payer coverage patterns where available. The publication also outlines commonly reported modifiers and identifies where input data were not provided.

This report helps clinicians, laboratory administrators, and policy analysts understand what CPT code 0021U represents, why it matters in national billing and diagnostic practice, and what to expect in terms of payer engagement and documentation requirements. Data not available in the input are noted where relevant.